- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00710593
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00936-5067
- University of Puerto Rico, Medical Sciences Campus
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Childrens Hospital of Los Angeles
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20010
- Childrens National Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Childrens Diagnostic & Treatment Center
-
Miami, Florida, United States, 33101
- University of Miami School of Medicine
-
Tampa, Florida, United States, 33606
- USF College of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Childrens Memorial Hospital
-
Chicago, Illinois, United States, 60612
- Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Health Sciences Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
New York
-
New York, New York, United States, 10128
- Mount Sinai Medical Center
-
The Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Childrens Hospital Of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St Jude Childrens Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Young women age 16 years and 0 days to 23 years and 364 days
- HIV-infection after the age of 9 years as documented by a positive result on any of the following licensed tests: any antibody test confirmed by Western blot, HIV-1 culture, HIV-1 DNA polymerase chain reaction (PCR), or plasma HIV-1 RNA > 1,000 copies/ml
- HIV treatment history that falls in one of the following categories:
Group A: ART naïve or if ART-exposed, has not received HAART for at least the six months prior to study entry Group B: Has been receiving HAART for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry
- Willingness to avoid pregnancy from study entry through the Week 28 visit for subjects of child-bearing potential, i.e., use of at least one barrier or hormonal method; e.g., condoms, Depo-Provera, oral contraceptive pills, etc. Subjects on antiretroviral (ARV) medications must use a barrier contraceptive method because ARV medications can make hormonal birth control less effective.
- Anticipated ability and willingness to complete all study vaccines and evaluations
- Ability and willingness to participate in the study by providing written informed consent
Exclusion Criteria:
- History of any prior vaccination with an HPV vaccine
- Active anogenital warts within three months prior to study entry) or history of cervical intraepithelial neoplasia (CIN) 2/3 (ever, must be documented by colposcopy)
- Previous allergic reaction to any constituents of the HPV vaccine
- Pregnancy
- Active substance use or dependence that, in the opinion of the site personnel, would interfere with adherence to the study
- Active opportunistic infection or current treatment for known or suspected active serious bacterial infection at the time of study entry
- Presence of any known > Grade 3 clinical or laboratory toxicity at the time of study entry (per the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Toxicity Tables, see ATN MOGO) with the exception of isolated Grade 3 serum total hyperbilirubinemia that is considered due to atazanavir (see Section 9.6 for definition of isolated total hyperbilirubinemia).
- Receipt of any routine vaccine within four weeks prior to study entry
- Receipt of any immune globulin or plasma product within six months prior study entry
- Receipt of any blood product or transfusion, other than immune globulin or plasma as noted above, within four weeks prior to study entry
- Receipt of any restricted medication listed in Section 5.3.2 within the four weeks preceding study entry
- Receipt of any other disallowed medication listed in Section 5.3.3 within the three months preceding study entry
- Thrombocytopenia or coagulation disorder that would contraindicate intramuscular injection
- Anticipation of long-term systemic corticosteroid therapy (more than 10 mg/day of prednisone or equivalent for > 2 consecutive weeks)
- Receipt of corticosteroid therapy at the above dose and duration within 3 months preceding study entry. Use of non-steroidal anti-inflammatory agents and inhaled or topical corticosteroids are not exclusion criteria
- Known or suspected disease of the immune system (other than HIV), i.e., malignancy, current or prior treatment for malignancy
- If other serious, acute or chronic medical or surgical conditions or contraindications are present during screening, the Protocol Team must be consulted to determine whether enrollment may interfere with the evaluation of the protocol objectives and for permission to proceed with the enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A: HAART naive or no HAART in past 6 months
Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry.
All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
|
All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
|
Active Comparator: B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months
Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry.
All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
|
All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV-6 Antibody Level (Geometric Mean Titer of HPV-6)
Time Frame: Week 28
|
The outcome measure for the primary objective is immunogenicity as measured by the GMT of HPV-6, -11, -16, -18 vaccine four weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose # 3 was administered at Week 24.
|
Week 28
|
HPV-11 Antibody Level (Geometric Mean Titer of HPV-11)
Time Frame: Week 28
|
The outcome measure for the primary objective is immunogenicity as measured by the GMTs of HPV-6, -11, -16, -18 vaccine four weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine Dose #3 was administered at Week 24.
|
Week 28
|
HPV-16 Antibody Level (Geometric Mean Titer of HPV-16)
Time Frame: Week 28
|
The outcome measure for the primary objective is immunogenicity as measured by the GMTs of HPV-6, -11, -16, -18 vaccine four weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose # 3 was administered at Week 24.
|
Week 28
|
HPV-18 Antibody Level (Geometric Mean Titer of HPV-18)
Time Frame: Week 28
|
The outcome measure for the primary objective is immunogenicity as measured by the GMTs of HPV-6, -11, -16, -18 vaccine four weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose #3 was administered at Week 24.
|
Week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of the HPV-6, -11, -16, -18 Vaccine Four Weeks After Vaccine Dose #3 as Measured as a Binary Variable (Responder vs. Non-responder) for HPV-6
Time Frame: Week 28
|
Subjects who had a greater than or equal to (>=) 20 Milli-Merck units (mMU)/milliliter (mL) response were classified as responders; subjects who had a less than (<) 20 mMU/mL response were classified as non-responders.
|
Week 28
|
Immunogenicity of the HPV-6, -11, -16, -18 Vaccine Four Weeks After Vaccine Dose #3 as Measured as a Binary Variable (Responder vs. Non-responder) for HPV-11
Time Frame: Week 28
|
Subjects who had a >= 16 mMU/mL were classified as responders; subjects who had a less than < 16 mMU/mL response were classified as non-responders.
|
Week 28
|
Immunogenicity of the HPV-6, -11, -16, -18 Vaccine Four Weeks After Vaccine Dose #3 as Measured as a Binary Variable (Responder vs. Non-responder) for HPV-16
Time Frame: Week 28
|
Subjects who had a >= 20 mMU/mL were classified as responders; subjects who had a less than < 20 mMU/mL response were classified as non-responders.
|
Week 28
|
Immunogenicity of the HPV-6, -11, -16, -18 Vaccine Four Weeks After Vaccine Dose #3 as Measured as a Binary Variable (Responder vs. Non-responder) for HPV-18
Time Frame: Week 28
|
Subjects who had a >= 24 mMU/mL were classified as responders; subjects who had a less than < 24 mMU/mL response were classified as non-responders.
|
Week 28
|
Number of Participants With At Least One Adverse Event Possibly, Probably, or Definitely Related to Vaccine
Time Frame: Entry, Week 8, and Week 24
|
When a subject had at least one adverse event or sign/symptom during the study after doses 1, 2 or 3, and the event was possibly, probably, or definitely related to vaccine, this subject was considered to have had a vaccine-associated adverse event, sign and/or symptom.
|
Entry, Week 8, and Week 24
|
Persistence of Immunogenicity of the HPV-6, -11, -16, and -18 Vaccine 24 Weeks Post Vaccine Dose #3 as Measured by the Geometric Mean Titers (GMT) of HPV-6.
Time Frame: Week 48
|
Persistence of immunogenicity as measured by geometric mean titers (GMT) to HPV-6, -11, -16, -18 vaccine 24 weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose #3 was administered at Week 24.
|
Week 48
|
Persistence of Immunogenicity of the HPV-6, -11, -16, and -18 Vaccine 24 Weeks Post Vaccine Dose #3 as Measured by the Geometric Mean Titers (GMT) of HPV-11.
Time Frame: Week 48
|
Persistence of immunogenicity as measured by geometric mean titers (GMT) to HPV-6, -11, -16, -18 vaccine 24 weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose # 3 was administered at Week 24
|
Week 48
|
Persistence of Immunogenicity of the HPV-6, -11, -16, and -18 Vaccine 24 Weeks Post Vaccine Dose #3 as Measured by the Geometric Mean Titers (GMT) of HPV-16.
Time Frame: Week 48
|
Persistence of immunogenicity as measured by geometric mean titers (GMT) to HPV-6, -11, -16, -18 vaccine 24 weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose # 3 was administered at Week 24
|
Week 48
|
Persistence of Immunogenicity of the HPV-6, -11, -16, and -18 Vaccine 24 Weeks Post Vaccine Dose #3 as Measured by the Geometric Mean Titers (GMT) of HPV-18.
Time Frame: Week 48
|
Persistence of immunogenicity as measured by geometric mean titers (GMT) to HPV-6, -11, -16, -18 vaccine 24 weeks after the administration of vaccine dose #3, measured as a continuous variable.
Vaccine dose # 3 was administered at Week 24
|
Week 48
|
Acquisition of HPV-6 DNA by Study Group and Study Visit (Week 24).
Time Frame: Week 24
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV-6 sero-negative by study group and study visit at Week 24.
|
Week 24
|
Acquisition of HPV-11 DNA by Study Group and Study Visit (Week 24).
Time Frame: Week 24
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV-11 sero-negative by study group and study visit at Week 24.
|
Week 24
|
Acquisition of HPV-16 DNA by Study Group and Study Visit (Week 24).
Time Frame: Week 24
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV-16 sero-negative by study group and study visit at Week 24.
|
Week 24
|
Acquisition of HPV-18 DNA by Study Group and Study Visit (Week 24).
Time Frame: Week 24
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV-18 sero-negative by study group and study visit at Week 24.
|
Week 24
|
Acquisition of HPV-6 DNA by Study Group and Study Visit (Week 48).
Time Frame: Week 48
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV sero-negative by study group and study visit at Week 48.
|
Week 48
|
Acquisition of HPV-11 DNA by Study Group and Study Visit (Week 48).
Time Frame: Week 48
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV sero-negative by study group and study visit at Week 48.
|
Week 48
|
Acquisition of HPV-16 DNA by Study Group and Study Visit (Week 48).
Time Frame: Week 48
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV sero-negative by study group and study visit at Week 48.
|
Week 48
|
Acquisition of HPV-18 DNA by Study Group and Study Visit (Week 48).
Time Frame: Week 48
|
Type-specific HPV DNA among subjects who were both HPV DNA negative and HPV sero-negative by study group and study visit at Week 48.
|
Week 48
|
Percentage of Participants Who Reported a Lower Need to Practice Safe Sex Following HPV Vaccination and the Percentage of Participants That Reported a Higher Need to Practice Safe Sex Following HPV Vaccination
Time Frame: Week 48
|
Participants' perceptions for the need to practice safe sex following HPV vaccination was measured using a safer sexual behaviors subscale, which was comprised of the following five questions: After getting vaccinated against HPV …
|
Week 48
|
Need for Safer Sexual Behaviors (NSSB) (Evaluated by Using the "12-item Knowledge About HPV and HPV Vaccine" Measure)
Time Frame: Week 48
|
To characterize young women's risk perceptions, sexual behaviors, and sexually transmitted infections (STI) diagnoses over the 48 weeks after initial vaccination, the relationship of baseline "12-item Knowledge About HPV and HPV Vaccine" measure was used to evaluate the need for safer sexual behaviors.
|
Week 48
|
Visit Compliance Via the Telephone Response System (TRS) Versus the Vaccine Report Card.
Time Frame: Day 1 through Week 24
|
Visit compliance is the total number of days participants actually called the TRS or completed the VRC divided by the total number of days expected to call the TRS or complete the VRC, multiplied by 100%.
|
Day 1 through Week 24
|
Adverse Events (AE) Reported Among Participants Who Were Randomized to the Telephone Response System (TRS) or Vaccine Report Card (VRC).
Time Frame: Day 1 through Week 24
|
Rate of AEs is the total number of AEs divided by the total number of participants.
The rate is not a percentage bur rather it could be above 1 or less than 1.
This outcome measure looked at number of AEs reported, by grade; number of AEs > Grade 3 identified; and number of AEs > Grade 3 evaluated within 24 or 48 hours.
|
Day 1 through Week 24
|
Collaborators and Investigators
Investigators
- Study Chair: Jessica A. Kahn, M.D., M.P.H., Adolescent Trials Network
- Study Chair: Kathleen Squires, M.D., Adolescent Trials Network
Publications and helpful links
General Publications
- Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K; Adolescent Trials Network for HIV/AIDS Interventions. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health. 2012 May;50(5):464-70. doi: 10.1016/j.jadohealth.2011.09.005. Epub 2011 Nov 4.
- Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):390-9. doi: 10.1097/QAI.0b013e3182676fe3.
- Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013 Sep;57(5):735-44. doi: 10.1093/cid/cit319. Epub 2013 May 10.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATN 064
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on HPV vaccine for strains -6, -11, -16, and -18
-
Chulalongkorn UniversityUnknownChronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease, Stage VThailand
-
National Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus-Related Cervical CarcinomaCosta Rica
-
Kenya Medical Research InstituteUniversity of WashingtonNot yet recruiting
-
Medstar Health Research InstituteMerck Sharp & Dohme LLCCompletedCervical Cancer | Warts | HpvUnited States
-
Shanghai Zerun Biotechnology Co.,LtdGuangxi Center for Disease Control and PreventionCompletedCervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
-
Prof. Jan PrinsCompleted
-
Merck Sharp & Dohme LLCCompletedPapillomavirus Infections
-
Alessandro GhelardiNot yet recruitingCervical Intraepithelial Neoplasia
-
Kenya Medical Research InstituteMerck Sharp & Dohme LLC; University of WashingtonCompletedHPV Infection | HPV Vaccine | HIV-1-infectionKenya
-
Merck Sharp & Dohme LLCCompleted